Zafgen Inc (NASDAQ:ZFGN) Shorts Increased By 13.18% As Of Jun 29, 2018

June 29, 2018 - By Daniel Cummings

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Change of 13.18% for Zafgen Inc (NASDAQ:ZFGN)’s shorted shares was noted. In June was published ZFGN’s total 677,600 shorted shares by FINRA. The 598,700 previous shares are up with 13.18%. Zafgen Inc (NASDAQ:ZFGN) has 171,500 shares average volume. It’ll cost 4 days for ZFGN to recover its previous position. Zafgen Inc’s shorted shares float is 3.01%.

The stock increased 3.96% or $0.38 during the last trading session, touching $9.98.Zafgen, Inc. has 539,372 shares volume, 114.87% up from normal. ZFGN is uptrending and has moved 60.78% since June 29, 2017. ZFGN outperformed by 48.21% the S&P500.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is worth $275.08 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Last it reported negative earnings.

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

Total analysts of 2 have positions in Zafgen (NASDAQ:ZFGN) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since January 5, 2018 according to StockzIntelligence Inc Zafgen has 2 analyst reports.

For more Zafgen, Inc. (NASDAQ:ZFGN) news published briefly go to: Benzinga.com, Benzinga.com, Globenewswire.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” published on June 28, 2018, “48 Biggest Movers From Yesterday” on June 29, 2018, “Zafgen Announces Proposed Offering of Common Stock” with a publish date: June 27, 2018, “Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to …” and the last “Zafgen: 3 Key Takeaways From ADA Abstracts” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.